Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment

Blood

Volumn 118, Issue 5, 2011, Pages 1350-1358

  Alizadeh, Ash A ^a   Gentles, Andrew J ^a   Alencar, Alvaro J ^b   Liu, Chih Long ^a   Kohrt, Holbrook E ^a   Houot, Roch ^a,c   Goldstein, Matthew J ^a   Zhao, Shuchun ^a   Natkunam, Yasodha ^a   Advani, Ranjana H ^a   Gascoyne, Randy D ^d   Briones, Javier ^e   Tibshirani, Robert J ^f   Myklebust, June H ^a,g   Plevritis, Sylvia K ^a   Lossos, Izidore S ^b   Levy, Ronald ^a,h  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f STANFORD LAW SCHOOL   (United States)

^g UNIVERSITY OF OSLO   (Norway)

^h CCSR South   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FORMALDEHYDE; LIM DOMAIN ONLY 2 PROTEIN; LIM PROTEIN; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 9 PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GERMINAL CENTER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LARGE CELL LYMPHOMA; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; TUMOR CELL; TUMOR MICROENVIRONMENT; VALIDATION PROCESS;

EID: 80051561099     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-345272     Document Type: Article

References (47)

1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
2. Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the Mab-Thera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379-391.
3. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117-4126. (Pubitemid 46211317)
4. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-1861. (Pubitemid 46348180)
5. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373-2380.
6. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069-6076.
7. Pui C-H, Evans WE. Treatment of Acute Lymphoblastic Leukemia. N Engl J Med. 2006;354(2):166-178. (Pubitemid 43076714)
8. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
9. Zelenetz A, Abramson J, Advani R, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2010;8(3):288-334.
10. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511. (Pubitemid 30082188)
11. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-1947.
12. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419-2430. (Pubitemid 43855045)
13. Monti S, Savage K, Kutok J, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105(5):1851-1861. (Pubitemid 40731764)
14. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100(17):9991-9996. (Pubitemid 37087056)
15. Swerdlow SH CE, Harris NL, Jaffe ES, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
16. Held G, Pfreundschuh M. Hematology: Germinal center or nongerminal center DLBCL? Nat Rev Clin Oncol. 2009;6(4):188-190.
17. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(6):995-1007. (Pubitemid 46638855)
18. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
19. Malumbres R, Chen J, Tibshirani R, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood. 2008;111(12):5509-5514.
20. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350(18):1828-1837. (Pubitemid 38917249)
21. Irish JM, Czerwinski DK, Nolan GP, Levy R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood. 2006;108(9):3135-3142.
22. Chen J, Byrne GEJ, Lossos IS. Optimization of RNA extraction from formalin-fixed, paraffin-embedded lymphoid tissues. Diagn Mol Pathol. 2007;16(2):61-72. (Pubitemid 47164737)
23. Lossos I, Czerwinski D, Wechser M, Levy R. Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia. 2003;17(4):789-795. (Pubitemid 36519378)
24. Alizadeh A, Gentles A, Lossos I, Levy R. Molecular outcome prediction in diffuse large-B-cell lymphoma. N Engl J Med. 2009;360(26):2794-2795.
25. Natkunam Y, Farinha P, Hsi ED, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol. 2008;26(3):447-454. (Pubitemid 351171698)
26. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159-2169. (Pubitemid 39507628)
27. Steidl C, Lee T, Shah S, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362(10):875-885.
28. Pollok K, Kim Y, Zhou Z, et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol. 1993;150(3):771-781. (Pubitemid 23133657)
29. Shuford W, Klussman K, Tritchler D, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med. 1997;186(1):47-55. (Pubitemid 27304846)
30. Houot R, Goldstein M, Kohrt H, et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood. 2009;114(16):3431-3438.
31. Natkunam Y, Zhao S, Mason DY, et al. The oncoprotein LMO2 is expressed in normal germinalcenter B cells and in human B-cell lymphomas. Blood. 2007;109(4):1636-1642. (Pubitemid 46239598)
32. Koscielny S. Why most gene expression signatures of tumors have not been useful in the clinic. Sci Transl Med. 2010;2(14):14ps2.
33. Varmus H. Ten Years On - The Human Genome and Medicine. N Engl J Med. 2010;362(21):2028-2029.
34. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8(1):68-74. (Pubitemid 34101731)
35. Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G. A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatics. 2008;24(19):2200-2208.
36. Choi WWL, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15(17):5494-5502.
37. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282. (Pubitemid 38029949)
38. Lossos I. Diffuse large B cell lymphoma: from gene expression profiling to prediction of outcome. Biol Blood Marrow Transplant. 2008;14(1):108-111. (Pubitemid 350286850)
39. Van Vlierberghe P, van Grotel M, Beverloo HB, et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood. 2006;108(10):3520-3529.
40. Ferrando AA, Look AT. Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol. 2003;40(4):274-280. (Pubitemid 37296777)
41. McCormack MP, Young LF, Vasudevan S, et al. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science. 2010;327(5967):879-883.
42. McCormack MP, Rabbitts TH. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2004;350(9):913-922. (Pubitemid 38252539)
43. Kohrt HE, Houot R, Goldstein MJ, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117(8):2423-2432.
44. Middendorp S, Xiao Y, Song J-Y, et al. Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma. Blood. 2009;114(11):2280-2289.
45. Rimsza LM, Roberts RA, Miller TP, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood. 2004;103(11):4251-4258. (Pubitemid 38685371)
46. Melero I, Shuford W, Newby S, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3(6):682-685. (Pubitemid 27264981)
47. Yang D-H, Ahn JS, Kim Y-K, et al. Comparing standard IPI with revised-IPI in patients with diffuse large B-cell lymphoma: which has a more differential potential for predicting the outcomes after R-CHOP chemotherapy [Abstract]. Blood. 2008;112(11):2003.